Alv B AS is a biotechnology company that specializes in the development of innovative immunotherapies for cancer treatment in pets, with the potential for application to humans as well. The company uses the ground-breaking Nebumet technology to target lung metastases, and has a particular focus on the treatment of solid tumors in dogs. With over 40 years of experience in the industry and several patent families, Alv B AS has positioned itself as a player with considerable expertise in its field.
The company aims to establish a global "center of excellence" for research into experimental cancer treatment for dogs and cats. Through the development of a unique drug pipeline within veterinary medicine, Alv B AS wants to make available data that can promote further research. Cancer is the most common cause of death in dogs and cats, and the company believes that studying cancer in these animals can provide valuable insights and solutions for treating humans.